11β-Hydroxysteroid Dehydrogenase Types 1 and 2: An Important Pharmacokinetic Determinant for the Activity of Synthetic Mineralo- and Glucocorticoids
The DOI matches its Crossref record; 33 of the 38 references it cites were found in a registry or an index.
Abstract
The 11beta-hydroxysteroid dehydrogenase (11beta-HSD) system plays a pivotal role in glucocorticoid (GC) and mineralocorticoid (MC) action. Although 11beta-HSD activities are important determinants for the efficacy of synthetic MCs and GCs, corresponding pharmacokinetic data are scanty. Therefore, we characterized 11beta-HSD profiles for a wide range of steroids often used in clinical practice. 11beta-HSD1 and 11beta-HSD2 were selectively examined in 1) human liver and kidney cortex microsomes, and 2) Chinese hamster ovarian cells stably transfected with 11beta-HSD1 or 11beta-HSD2 expression vectors. Both systems produced concordant evidence for the following conclusions. Oxidation of steroids by 11beta-HSD2 is diminished if they are fluorinated in position 6alpha or 9alpha (e.g. in dexamethasone) or methylated at 2alpha or 6alpha (in methylprednisolone) or 16alpha or 16beta, by a methylene group at 16 (in prednylidene), methyloxazoline at 16, 17 (in deflazacort), or a 2-chlor configuration. Whereas the methyl groups also decrease reductase activity (steric effects), fluorination increases reductase activity (negative inductive effect), leading to a shift to reductase activity. This may explain the strong MC activity of 9alpha-fluorocortisol and should be considered in GC therapy directed to 11beta-HSD2-expressing tissues (kidney, colon, and placentofetal unit). 11beta-HSD2 oxidation of prednisolone is more effective than that of cortisol, explaining the reduced MC activity of prednisolone compared with cortisol. Reduction by 11beta-HSD1 is diminished by 16alpha-methyl, 16beta-methyl, 2alpha-methyl, and 2-chlor substitution, whereas it is increased by the Delta(1)-dehydro configuration in prednisone, resulting in higher hepatic first pass activation of prednisone compared with cortisone. To characterize a GC or a MC as substrate for the different 11betaHSDs may be essential for an optimized steroid therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is the reason why, when these compounds are injected in a tissue without 11β-HSD1, they have no biological activity.”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [72]
Experimental — accuracy not yet measuredIn the citing paper
“The biological activity of cortisone and prednisone depends on first pass activation by hepatic 11β-hydroxysteroid-dehydrogenase type 1 (11β-HSD1) [72].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tannin, G. M., Agarwal, A. K., Monder, C., New, M. I., & White, P. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55351-5 · Cited by 436
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Jamieson, P. M., Chapman, K. E., Edwards, C. R. W., & Seckl, J. R. (1995) · Endocrinology · doi:10.1210/en.136.11.4754 · Cited by 301
Krozowski, Z., MaGuire, J. A., Stein-Oakley, A. N., Dowling, J., Smith, R. E., & Andrews, R. K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608280 · Cited by 252
Barf, T., Vallgårda, J., Emond, R., Häggström, C., Kurz, G., Nygren, A., Larwood, V., Mosialou, E., Axelsson, K., Olsson, R., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025530f · Cited by 211
Immunohistochemical Localization of Type 1 11β-Hydroxysteroid Dehydrogenase in Human Tissues1
Ricketts, M. L., Verhaeg, J. M., Bujalska, I., Howie, A. J., Rainey, W. E., & Stewart, P. M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.4.4706 · Cited by 197
Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues.
Smith, R. E., Maguire, J. A., Stein-Oakley, A. N., Sasano, H., Takahashi, K., Fukushima, K., & Krozowski, Z. S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784076 · Cited by 146
Conversion of cortisone to cortisol and prednisone to prednisolone.
Jenkins, J. S., & Sampson, P. A. (1967) · BMJ · doi:10.1136/bmj.2.5546.205 · Cited by 141
BALLARD, P. L., CARTER, J. P., GRAHAM, B. S., & BAXTER, J. D. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-2-290 · Cited by 135
Bujalska, I. J., Shimojo, M., Howie, A., & Stewart, P. M. (1997) · Steroids · doi:10.1016/s0039-128x(96)00163-8 · Cited by 124
Cited by
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
“In addition to its role in glucocorticoid metabolism, which includes the synthetic glucocorticoids prednisolone and betamethasone, but not dexamethasone (154), 11 -HSD1 catalyzes other steroid and sterol interconversions.”
BackgroundPharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886
“[76] The activity of 11β-HSD2 varies depending tial functions are used to describe this cortisol deon the type of glucocorticoid,[75,76] which explains to cline after prednisolone[28,29] whereas monoexposome extent the different mineralocorticoid activi- nential functions are used for the cortisol decline ties of diff…”
BackgroundMethodA General Introduction to Glucocorticoid Biology
Timmermans, S., Souffriau, J., & Libert, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01545 · Cited by 609
Weinstein, R. S., Wan, C., Liu, Q., Wang, Y., Almeida, M., O’Brien, C. A., Thostenson, J., Roberson, P. K., Boskey, A. L., Clemens, T. L., et al. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00545.x · Cited by 276
“11b-HSD2 inactivates both synthetic and naturally occurring glucocorticoids by oxidizing their 11b-hydroxy groups to inert 11b-keto forms, thereby preventing binding to the glucocorticoid receptor (Sandeep & Walker, 2001; Diederich et al., 2002).”
BackgroundThe clinical use of corticosteroids in pregnancy
Kemp, M. W., Newnham, J. P., Challis, J. G., Jobe, A. H., & Stock, S. J. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmv047 · Cited by 216
“…and prednisone is mediated predominantly by 11 b -hydroxysteroid dehydrogenase (11 b -HSD), with 11 b -HSD1 primarily acting as a reductase converting prednisone to active prednisolone, and 11 b -HSD2 acting primarily as an oxidase, converting prednisolone to prednisone (Diederich et al. , 2002).”
BackgroundTreating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
Grossmann, C., Scholz, T., Rochel, M., Bumke-Vogt, C., Oelkers, W., Pfeiffer, A., Diederich, S., & Bahr, V (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510397 · Cited by 212
“Besides transactivation, MC activity in target tissues depends on prereceptor metabolism by 11b-hydroxysteroid-dehydrogenase type 2 (11b-HSD2), which is co-localized with the MR and inactivates 11-hydroxysteroids to their corresponding 11-oxoderivatives ( 39 ).”
BackgroundPregnancy and pituitary disorders
Karaca, Z., Tanriverdi, F., Unluhizarci, K., & Kelestimur, F. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0923 · Cited by 191
Glucocorticoid-induced osteoporosis: 2019 concise clinical review
Adami, G., & Saag, K. G. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04906-x · Cited by 183
Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102201 · Cited by 181
Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone
Løvås, K., Gjesdal, C. G., Christensen, M., Wolff, A. B., Almås, B., Svartberg, J., Fougner, K. J., Syversen, U., Bollerslev, J., Falch, J. A., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0880 · Cited by 163
Tegethoff, M., Pryce, C., & Meinlschmidt, G. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0014 · Cited by 140
Why is the management of glucocorticoid deficiency still controversial: a review of the literature
Crown, A., & Lightman, S. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02320.x · Cited by 128
Bergmann, T. K., Barraclough, K. A., Lee, K., & Staatz, C. E. (2012) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0007-8 · Cited by 146
Chapman, K. E., Coutinho, A. E., Zhang, Z., Kipari, T., Savill, J. S., & Seckl, J. R. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.02.002 · Cited by 120
Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting
Lishner, M., Avivi, I. M., Apperley, J. F., Dierickx, D., Evens, A. M., Fumagalli, M., Nulman, I., Oduncu, F. S., Peccatori, F. A., Robinson, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4445 · Cited by 124
Heine, V. M., & Rowitch, D. H. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36376 · Cited by 112
Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
Auchus, R. J., Yu, M. K., Nguyen, S., & Mundle, S. D. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0167 · Cited by 119
Reconciling the nutritional and glucocorticoid hypotheses of fetal programming
Cottrell, E. C., Holmes, M. C., Livingstone, D. E., Kenyon, C. J., & Seckl, J. R. (2012) · The FASEB Journal · doi:10.1096/fj.12-203489 · Cited by 102
Potentiation of Glucocorticoid Activity in Hypoxia through Induction of the Glucocorticoid Receptor
Leonard, M. O., Godson, C., Brady, H. R., & Taylor, C. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.2250 · Cited by 100
“Together with the fact that dexamethasone does not need to be reduced by these enzymes for activation (32) these data indicate that the 11 -HSD enzymes play no role in influencing glucocorticoid sensitivity in hypoxia.”
BackgroundGlucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
Porta, S., Danza, Ã., Saavedra, M. A., Carlomagno, A., Goizueta, M. C., Vivero, F., & Ruiz‐Irastorza, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092709 · Cited by 116
Tomlinson, J. W., Sherlock, M., Hughes, B., Hughes, S. V., Kilvington, F., Bartlett, W., Courtney, R., Rejto, P., Carley, W., & Stewart, P. M. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2325 · Cited by 98
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
Heier, C. R., Yu, Q., Fiorillo, A. A., Tully, C., Tucker, A., Mázala, D. A. G., Uaesoontrachoon, K., Srinivassane, S., Damsker, J. M., Hoffman, E. P., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800186 · Cited by 97
“De fl azacort, on the other hand, is an 11 β - hydroxysteroid developed as a more targeted anti-in fl ammatory GR agonist with differentiated tissue-speci fi c bioavailability (Hahn et al, 1981; Diederich et al, 2002).”
BackgroundMinireview: Live and Let Die: Molecular Effects of Glucocorticoids on Bone Cells
Hofbauer, L. C., & Rauner, M. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0069 · Cited by 91
Pharmacologic Characteristics of Corticosteroids
Samuel, S., Nguyen, T., & Choi, H. A. (2017) · Journal of Neurocritical Care · doi:10.18700/jnc.170035 · Cited by 118
“Cortisol has 21 carbon atoms with a 2-carbon side chain attached to position 17 and methyl groups at C-10 and C-13.(10) Chemical alterations at various positions of the steroid molecule lead to synthetic analogous of cortisol with increased glucocorticoid and/or mineralocorticoid activities.”
BackgroundInfluentialCorticosteroids, Pregnancy, and HELLP Syndrome: A Review
Heimel, P. J. V. R., Franx, A., Schobben, A. F. A. M., Huisjes, A. J. M., Derks, J. B., & Bruinse, H. W. (2004) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000150346.42901.07 · Cited by 97
Carbonyl reduction pathways in drug metabolism
Malátková, P., & Wsól, V. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.853078 · Cited by 88
“Prednisone is reduced to prednisolone by 11b-HSD1, as demonstrated in vitro (Diederich et al., 2002) and in vivo (Tomlinson et al., 2007).”
BackgroundInfluentialPharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome
Schijvens, A. M., ter Heine, R., de Wildt, S. N., & Schreuder, M. F. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3929-z · Cited by 92
Antenatal Dexamethasone Treatment Leads to Changes in Gene Expression in a Murine Late Placenta
Baisden, B. L., Sonne, S., Joshi, R., Ganapathy, V., & Shekhawat, P. (2007) · Placenta · doi:10.1016/j.placenta.2007.04.002 · Cited by 79
“In contrast 11βHSD2 which is a high-affinity NAD+-dependent unidirectional dehydrogenase converts cortisol into its inactive metabolite cortisone and also inactivates prednisolone in a similar fashion [14,15].”
BackgroundRegulation of ENaC-mediated sodium transport by glucocorticoids in Reissner's membrane epithelium
Kim, S. H., Kim, K. X., Raveendran, N. N., Wu, T., Pondugula, S. R., & Marcus, D. C. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00338.2008 · Cited by 74
Garbrecht, M. R., Klein, J. M., Schmidt, T. J., & Snyder, J. M. (2006) · Neonatology · doi:10.1159/000088653 · Cited by 72
“GC action in peripheral tissues is thought to be regulated by (1) the activation/inhibition of the hypothalamic-pituitary-adrenal (HPA) axis (i.e., physiological feedback mechanisms regulating adrenal GC biosynthesis and release), (2) the reversible binding of cortisol to transcortin, and/or (3) the differential expre…”
BackgroundGlucocorticoid Therapy and Adrenal Suppression
Nicolaides, N. C., Pavlaki, A. N., Alexandra, M. A. M., & Chrousos, G. P. (2011) · Europe PMC (PubMed Central) · Cited by 71
Sensitivity of bone to glucocorticoids
COOPER, M. S. (2004) · Clinical Science · doi:10.1042/cs20040070 · Cited by 67
Solano, M. E., Holmes, M. C., Mittelstadt, P. R., Chapman, K. E., & Tolosa, E. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0575-z · Cited by 67
Jakobsson, A., Jörgensen, J. A., & Jacobsson, A. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00045.2005 · Cited by 61
Quinkler, M., Ekman, B., Marelli, C., Uddin, S., Zelissen, P., Murray, R. D., & _, _. (2017) · Endocrine Connections · doi:10.1530/ec-16-0081 · Cited by 59
The 11-ketosteroid 11-ketodexamethasone is a glucocorticoid receptor agonist
Rebuffat, A., Tam, S., Nawrocki, A. R., Baker, M. E., Frey, B. M., Frey, F. J., & Odermatt, A. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.11.027 · Cited by 69
Prednisone Pharmacokinetics During Pregnancy and Lactation
Ryu, R. J., Easterling, T. R., Caritis, S. N., Venkataramanan, R., Umans, J. G., Ahmed, M. S., Clark, S. M., Kantrowitz‐Gordon, I., Hays, K. E., Bennett, B., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1122 · Cited by 56
Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency
Oprea, A., Bonnet, N., Pollé, O. G., & Lysy, P. A. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818821294 · Cited by 69
11β-Hydroxysteroid dehydrogenase 1: Regeneration of active glucocorticoids is only part of the story
Odermatt, A., & Klusoňová, P. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.08.011 · Cited by 59
Filipsson, H., & Johannsson, G. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0319 · Cited by 50
Gomez-Gomez, A., Miranda, J., Feixas, G., Arranz Betegon, A., Crispi, F., Gratacós, E., & Pozo, O. J. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105520 · Cited by 50
Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond
Konstantakou, P., Mastorakos, G. P., Vrachnis, N., Tomlinson, J., & Valsamakis, G. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2016.1171308 · Cited by 53
“As well as cortisone, its substrates include various synthetic corticosteroids (prednisolone, betamethasone- not dexamethasone), anti-inflammatory agents [61], bile acids [62], and it has an important detoxify role in the body [63,64].”
BackgroundDrug choices in autoimmune hepatitis: Part B – nonsteroids
Czaja, A. J. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.38 · Cited by 49
Risks and benefits of corticosteroids in arthritic diseases in the clinic
Πέττα, Ι., Peene, I., Elewaut, D. S., Vereecke, L., & Bosscher, K. D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.009 · Cited by 53
Risk for osteoporosis and fracture with glucocorticoids
Urquiaga, M., & Saag, K. G. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101793 · Cited by 49
Deng, J., Chalhoub, N. E., Sherwin, C. M. T., Li, C., & Brunner, H. I. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.03.010 · Cited by 48
Enzymology and Molecular Biology of Glucocorticoid Metabolism in Humans
Blum, A., & Maser, E. (2003) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(03)75006-5 · Cited by 50
Buchwald, P. (2007) · Steroids · doi:10.1016/j.steroids.2007.10.001 · Cited by 43
Riehl, G., Reisch, N., Roehle, R., Claahsen van der Grinten, H., Falhammar, H., & Quinkler, M. (2020) · Clinical Endocrinology · doi:10.1111/cen.14149 · Cited by 39
Zhang, J., Ge, P., Liu, J., Luo, Y., Guo, H., Zhang, G., Xu, C., & Chen, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512138 · Cited by 47
“The opposite process occurs when 11β-HSD 2 oxidizes prednisolone/dehydrocortisol [44,45].”
BackgroundGraf, K., Murrieta-Coxca, J. M., Vogt, T., Besser, S., Geilen, D., Kaden, T., Bothe, A.-K., Prieto, D. M. M., Amiri, B., Schaller, S., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528748 · Cited by 41
Pozo, Ó. J., Marcos, J., Matabosch, X., Ventura, R., & Segura, J. (2012) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6129 · Cited by 35
Drug choices in autoimmune hepatitis: Part A – steroids
Czaja, A. J. (2012) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.12.40 · Cited by 34
Treatment of children with infantile spasms: A network meta‐analysis
Jain, P., Sahu, J. K., Horn, P. S., Chau, V., Go, C., Mahood, Q., & Arya, R. (2022) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15330 · Cited by 30
“Prednisone is a prodrug and needs to be converted to active prednisolone by hepatic 11- βhydroxysteroid dehydrogenase.(49) A low dose of prednisone was reported to be inferior to ACTH.”
BackgroundReplacement therapy for Addison's disease: recent developments
Løvås, K., & Husebye, E. S. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.497 · Cited by 32
“Prednisolone is effectively inactivated by the placental 11 β -HSD [30] , and is probably of less concern during pregnancy.”
BackgroundLiu, Y. U., Park, F., Pietrusz, J. L., Jia, G., Singh, R. J., Netzel, B. C., & Liang, M. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00067.2007 · Cited by 32
Absence of 11-keto reduction of cortisone and 11-ketotestosterone in the model organism zebrafish
Tsachaki, M., Meyer, A., Weger, B. D., Kratschmar, D. V., Tokarz, J., Adamski, J., Belting, H., Affolter, M., Dickmeis, T., & Odermatt, A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0495 · Cited by 34
Ayyar, V. S., Almon, R. R., DuBois, D. C., Sukumaran, S., Qu, J., & Jusko, W. J. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2017.03.007 · Cited by 31
Paitz, R. T., Bukhari, S. A., & Bell, A. M. (2016) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2015.2838 · Cited by 38
Siggelkow, H., Etmanski, M., Bozkurt, S., Groβ, P., Koepp, R., Brockmöller, J., & Tzvetkov, M. V. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1418 · Cited by 29
Garbrecht, M. R., Krozowski, Z. S., Snyder, J. M., & Schmidt, T. J. (2006) · Steroids · doi:10.1016/j.steroids.2006.06.001 · Cited by 30
Sai, S., Nakagawa, Y., Yamaguchi, R., Suzuki, M., Sakaguchi, K., Okada, S., Seckl, J. R., Ohzeki, T., & Chapman, K. E. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.07.002 · Cited by 32
“Dexamethasone is poorly metabolised by 11β-HSD enzymes, whereas prednisone/ prednisolone are readily metabolized [14].”
InfluentialOvercoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Bryant, G., Wang, L., & Mulholland, D. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071542 · Cited by 31
“as the conversion of the active metabolite prednisolone to its inactive form prednisone [96].”
BackgroundYe, L., Xie, W., Strong, J. A., & Zhang, J. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000277 · Cited by 30
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice
Adami, G., Rahn, E. J., & Saag, K. G. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19876468 · Cited by 30
Chen, H. C., Yip, T., Lee, J. K., Juliani, J., Sernia, C., Hill, A. F., Lavidis, N. A., & Spiers, J. G. (2020) · Antioxidants · doi:10.3390/antiox9090853 · Cited by 30
Endogenous Glucocorticoid Metabolism in Bone: Friend or Foe
Martin, C., Cooper, M. S., & Hardy, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.733611 · Cited by 26
Replacement therapy in Addison?s disease
Løvås, K., & Husebye, E. S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.12.2145 · Cited by 30
“The synthetic glucocorticoids have variable affinity to the 11β-HSD enzymes, which may result in variable pharmacodynamic effects [30].”
BackgroundReference ranges for the urinary steroid profile in a Latin‐American population
Brito, D. M., Vidal, M. T. C., de la Torre, X., García, V., Lozano, O. L., & Fraga, M. G. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1448 · Cited by 21
Nethathe, G. D., Lipman, J., Anderson, R., Fuller, P. J., & Feldman, C. H. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.10.034 · Cited by 27
Sæves, I., Line, P., & Bergan, S. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31825ee3f8 · Cited by 21
“Synthetic glucocorticoids like prednisolone and prednisone are substrates for 11b-HSD and are interconverted in the same way.(4) The enzyme 11bHSD1 is expressed in the liver, adrenal cortex, adipose tissue, lungs, gonads, pituitary gland, and the central nervous system and supplies active cortisol to the GR.”
BackgroundMartinerie, L., Pussard, E., Méduri, G., Delezoide, A., Boileau, P., & Lombès, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031949 · Cited by 23
“rone [12].”
Prenatal Glucocorticoids: Short-Term Benefits and Long-Term Risks
Manojlovic-Stojanoski, M., Nestorovic, N., & Milosevic, V. (2012) · Glucocorticoids - New Recognition of Our Familiar Friend · doi:10.5772/51106 · Cited by 19
The metabolism of steroids, toxins and drugs by 11β-hydroxysteroid dehydrogenase 1
Zhou, H.-Y., Hu, G., Lian, Q., Morris, D. J., & Ge, R. (2011) · Toxicology · doi:10.1016/j.tox.2011.11.012 · Cited by 22
CYP260B1 acts as 9α-hydroxylase for 11-deoxycorticosterone
Litzenburger, M., & Bernhardt, R. (2017) · Steroids · doi:10.1016/j.steroids.2017.08.006 · Cited by 19
“These 9α-halo-11β-hydroxysteroids diminish the oxidation of the 11hydroxyl group providing an increased duration of activity on the receptor which leads to their high anti-inflammatory effect [39].”
Patel, P., Hardy, R., Sumathi, V. P., Bartle, G., Kindblom, L., Grimer, R. J., Bujalska, I. J., Stewart, P. M., Rabbitt, E. H., Gittoes, N. J. L., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0079 · Cited by 20
Wu, N., Katz, D. A., & An, G. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1925 · Cited by 17
Cortisol levels are associated with mortality risk in hemodialysis patients
Gracia-Iguacel, C., González‐Parra, E., Egido, J., Lindholm, B., Mahíllo, I., Carrero, J. J., & Ortíz, A. (2014) · Clinical Nephrology · doi:10.5414/cn108311 · Cited by 19
“In other sites (classically in hippocampus and also probably in myocardium, vascular smooth muscle and adipose tissue) which lack 11β-HSD2, cortisol occupies MRs in competition with much lower prevailing concentrations of aldosterone [7].”
Background11β-Hydroxysteroid Dehydrogenase Type 1 as a Potential Treatment Target in Cardiovascular Diseases
Kupczyk, D., Studzińska, R., Kołodziejska, R., Baumgart, S., Modrzejewska, M., & Woźniak, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206190 · Cited by 21
Fischer, A., Otte, C., Krieger, T., Nicholls, R. A., Krüger, S., Ziegler, K. J., Schulz, K., Heesen, C., & Gold, S. M. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.03.001 · Cited by 16
“We found group differences for hydrocortisone, which can be inactivated by the enzyme 11b-hydroxysteroid dehydrogenase 2 (11bHSD2), but not dexamethasone, a weak 11b-HSD substrate (Diederich et al., 2002).”
BackgroundNarrative Review: Glucocorticoids in Alcoholic Hepatitis—Benefits, Side Effects, and Mechanisms
Lü, H. (2022) · Journal of Xenobiotics · doi:10.3390/jox12040019 · Cited by 13
Bakar, M. H. A., Khalid, M. S. F. M., Shahril, N. S. N., Shariff, K. A., & Karunakaran, T. (2021) · BioFactors · doi:10.1002/biof.1793 · Cited by 14
“Several lines of evidence indicate that increased 11βHSD1 gene promotes pro-inflammatory conditions and lipolysis-mediated hypertrophy in adipose tissue, resulting in the development of insulin resistance, and obesity.(3,5,32) In the present study, rats fed with HFrD exhibited with considerably diminished expression l…”
BackgroundMethodNgaosuwan, K., Johnston, D. G., Godsland, I. F., Cox, J., Majeed, A., Quint, J. K., Oliver, N. S., & Robinson, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab347 · Cited by 14
Liu, Y., Park, F., Pietrusz, J. L., Jia, G., Singh, R., Netzel, B. C., & Liang, M. (2008) · The FASEB Journal · doi:10.1096/fasebj.22.1_supplement.1162.7 · Cited by 12
In vivo and in vitro metabolism of dexamethasone in the camel
Alkatheeri, N. A., Wasfi, I. A., Lambert, M. A., Albo, A. G., & Nebbia, C. (2005) · The Veterinary Journal · doi:10.1016/j.tvjl.2005.06.003 · Cited by 13
Pharmacology of drugs used in autoimmune dermatopathies in cats and dogs: A narrative review
Tham, H. L., & Davis, J. L. (2024) · Veterinary Dermatology · doi:10.1111/vde.13253 · Cited by 11
Viglioli, M., Rizzo, S. M., Alessandri, G., Fontana, F., Milani, C., Turroni, F., Mancabelli, L., Croci, N., Rivara, S., Vacondio, F., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124663 · Cited by 14
Pawlak, P., Burren, A., Seitz, A., Glauser, G., & Pietsch, C. (2022) · Aquaculture Research · doi:10.1111/are.15994 · Cited by 12
Oestlund, I., Snoep, J. L., Schiffer, L., Wabitsch, M., Arlt, W., & Storbeck, K. (2023) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2023.106436 · Cited by 13
Martinerie, L., Viengchareun, S., Méduri, G., Kim, H., Luther, J. M., & Lombès, M. (2011) · Endocrinology · doi:10.1210/en.2010-1460 · Cited by 17
Christakoudi, S., Runglall, M., Mobillo, P., Rebollo‐Mesa, I., Tsui, T.-L., Nova‐Lamperti, E., Norris, S., Kamra, Y., Hilton, R. M., Bhandari, S., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.01.021 · Cited by 11
Hepatoprotective functions of jujuboside B
Kim, C., Jeong, Y. H., Kim, N., Ryu, S. H., & Bae, J. (2022) · Journal of Natural Medicines · doi:10.1007/s11418-022-01648-9 · Cited by 11
Salton, F., Confalonieri, P., Meduri, G. U., Mondini, L., Trotta, L., Barbieri, M., Bozzi, C., Torregiani, C., Lerda, S., Bellan, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16070924 · Cited by 8
“Dexamethasone and methylprednisolone, unlike hydrocortisone (see Figure 2), are not substrates to the 11β-HSD system, which makes their use preferable in the treatment of ARDS [31].”
BackgroundIyer-Bierhoff, A., Wieczorek, M., Peter, S. M., Ward, D., Bens, M., Vettorazzi, S., Guehrs, K.-H., Tuckermann, J. P., & Heinzel, T. (2024) · iScience · doi:10.1016/j.isci.2024.108943 · Cited by 12
Glucocorticoids: Biochemical Group That Play Key Role in Fetal Programming of Adult Disease
Mohammed, A. (2012) · InTech eBooks · doi:10.5772/50798 · Cited by 9
Vulto, A., Minović, I., de Vries, L. V., Timmermans, A. C., van Faassen, M. H. J. R., Neto, A. W. G., Touw, D. J., de Jong, M. F. C., van Beek, A. P., Dullaart, R. P. F., et al. (2020) · Clinical Transplantation · doi:10.1111/ctr.13824 · Cited by 9
“Fractional K excretion (%) 20 [15-26] 12 [10-15] <.”
Metabolism of Synthetic Steroids by the Human Placenta
Bähr, V., Oelkers, W., Pfeiffer, A. F. H., & Diederich, S. (2006) · Placenta · doi:10.1016/j.placenta.2006.05.004 · Cited by 8
Meduri, G. U., & Chrousos, G. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817558-3.00012-3 · Cited by 8
Metadata
- Authors
- Diederich, S., Eigendorff, E., Burkhardt, P., Quinkler, M., Bumke-Vogt, C., Rochel, M., Seidelmann, D., Esperling, P., Oelkers, W., & Bähr, V.
- Affiliations
- Freie Universität Berlin (DE)
- Department of Endocrinology, Diabetes, and Nutrition, Klinikum Benjamin Franklin, Freie Universität Berlin (S.D., E.E., P.B., M.Q., C.B.-V., M.R., W.O., V.B.), 12200 Berlin, Germany
- Research Laboratories of Schering AG (D.S., P. E.), 12200 Berlin, Germany
- Corresponding author
- Diederich, Sven
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-12-01
- Volume
- 87
- Issue
- 12
- Pages
- 5695-5701
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2026750991
- Cited by
- 154
- References
- 38
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 5 · 2020: 4 · 2019: 12 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 6 · 2013: 8 · 2012: 14
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- 11β-hydroxysteroid dehydrogenase, 11β-hydroxysteroid dehydrogenase type 1, 11β-hydroxysteroid dehydrogenase type 2, glucocorticoids, mineralocorticoids, steroid metabolism, pharmacokinetics, steroid structure-activity relationship, prednisolone, dexamethasone, methylprednisolone, deflazacort, hepatic first-pass metabolism, renal cortex, liver microsomes, CHO cells, glucocorticoid therapy
- MeSH terms
- Animals, Glucocorticoids, Cricetinae, Humans, Hydroxysteroid Dehydrogenases, Kidney Cortex, Microsomes, Microsomes, Liver, Mineralocorticoids, Oxidation-Reduction, Substrate Specificity, Transfection, CHO Cells, 11-beta-Hydroxysteroid Dehydrogenase Type 1, 11-beta-Hydroxysteroid Dehydrogenase Type 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.